AR062795A1 - Marcacion con fluor radioactivo para diagnostico por imagenes - Google Patents
Marcacion con fluor radioactivo para diagnostico por imagenesInfo
- Publication number
- AR062795A1 AR062795A1 ARP070104086A ARP070104086A AR062795A1 AR 062795 A1 AR062795 A1 AR 062795A1 AR P070104086 A ARP070104086 A AR P070104086A AR P070104086 A ARP070104086 A AR P070104086A AR 062795 A1 AR062795 A1 AR 062795A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- heteroaryl
- group
- aralkyl
- alkyl
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title 1
- 230000002285 radioactive effect Effects 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 7
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 7
- 150000002431 hydrogen Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 238000003682 fluorination reaction Methods 0.000 abstract 1
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0834—Compounds having one or more O-Si linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0896—Compounds with a Si-H linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/12—Organo silicon halides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C07K7/086—Bombesin; Related peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nuclear Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicacion 1: Un compuesto caracterizado porque tiene la formula química general (1) en donde X representa un grupo saliente adecuado para fluoracion seleccionado entre el grupo que comprende hidrogeno y OR3, en donde R3 representa hidrogeno, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo, heteroarilo o aralquilo, R1 y R2 se seleccionan, en forma independiente, entre el grupo que comprende hidrogeno, C1-10 lineal y ramificado, arilo, heteroarilo y aralquilo, -B1- se selecciona entre el grupo que comprende -[CH2]m-D-[CH2)n-A-, en donde n y m son, en forma independiente, cualquier numero entero entre 0 y 5, -D- representa una union, -S-, -O- o NR4-, en donde R4 representa hidrogeno, alquilo C1-10, arilo, heteroarilo o aralquilo, A representa alquilo, arilo sustituido o no sustituido o heteroarilo, E-Z1-Y1- representa una porcion seleccionada entre el grupo que comprende EO-C(=O)-, ENR5-C(=O)-, EC(=O)-O-, EC(=O)-NR5-, ENR5-SO2, -ESO2-NR5-, E-O-, E-(S)p-, E-NR5-, ENR6C(=O)-NR7-, ENR6-C(=O)NR7-, ENR6C(=S)-NR7-, ENR6-C(=S)NR7-, EO-C(=O)O-, EOC(=O)-O-, EOC(=S)-O-, EO-C(=S)O-, en donde el enlace simple largo que se muestra explícitamente en las formulas (2) es el enlace entre Z1 y Y1, y en donde las flechas que figuran en las formulas precedentes indican el enlace entre Z1 y Y1, R5, R6 y R7 representan, en forma independiente, hidrogeno, alquilo C1-10, arilo, heteroarilo o aralquilo lineal o ramificado, p es cualquier numero entero entre 1 y 3, y en donde E-Z1- es un radical agente de direccionamiento y E- es una biomolécula, o -B2- representa un alquil C1-10-, -aril- sustituido o no sustituido o -heteroarilo- sustituido o no sustituido, -Y2- se selecciona entre el grupo que comprende una union, - C(=O)-, -SO2-, -C(=O)-(CH2)d-, -S(=O)-, -C(=O)-C:::C-, -C(=O)-[CH2]m-D-[CH2]n-, -SO2-[CH2]m-D-[CH2]n-, -O-C(=O), -NR10-, -O-, -(S)p-, -NR12-C(=O)-, -NR12-C(=S)-, -O-C(=S)-, -cicloalquil C1-6-, -alquenil-, -heterocicloalquil-, -aril- sustituido o no sustituido, -heteroaril- sustituido o no sustituido, -aralquil-, -heteroaralquil-, -alquiloxi, -ariloxi-, -aralcoxi -NR13-SO2-, -SO2-NR13-, -O-C(=O)-NR13-, -NR12-C(=O)-NR13, -NH-NH- o -O-NH-, en donde d es un numero entero de 1 a 6, m y n son, en forma independiente, cualquier numero entero entre 0 y 5, -D- representa una union, - S-, -O- o -NR9-, en donde R9 representa hidrogeno, alquilo C1-10, arilo, heteroarilo o aralquilo, p es un numero entero de 1 a 3, R10 y R13 se seleccionan, en forma Independiente, entre el grupo que comprende hidrogeno, alquilo C1-10 sustituido o no sustituido lineal o ramificado, arilo, heteroarilo y aralquilo y R13 representa hidrogeno, alquilo C1-10 sustituido o no sustituido lineal o ramificado, arilo, cicloalquilo, heterocicloalquilo, heteroarilo, aralquilo o heteroaralquilo, en donde E-Z2- es un agente de direccionamiento radical, en donde E es una biomolécula y Z2 representa una porcion seleccionada entre el grupo que comprende una union y un separador, en donde el separador es una secuencia de aminoácidos natural o artificial o un grupo no aminoácido y una sal aceptable para uso farmacéutico de un ácido inorgánico u orgánico del misma, un hidrato, complejo, éster, amida, solvato y prodroga del mismo.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06076823A EP1908472A1 (en) | 2006-10-02 | 2006-10-02 | Silicon derivatives for PET imaging |
| EP06076869A EP1911452A1 (en) | 2006-10-11 | 2006-10-11 | Silicon-derivates for PET-Imaging |
| EP07090043A EP1970064A1 (en) | 2007-03-12 | 2007-03-12 | Silicon-derivatives for pet-imaging |
| EP07090079A EP1985624A3 (en) | 2007-04-23 | 2007-04-23 | Single step method of radiofluorination of biologically active compounds or biomolecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062795A1 true AR062795A1 (es) | 2008-12-03 |
Family
ID=39030886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104086A AR062795A1 (es) | 2006-10-02 | 2007-09-14 | Marcacion con fluor radioactivo para diagnostico por imagenes |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20090035215A1 (es) |
| EP (1) | EP2074135A2 (es) |
| JP (1) | JP2010505776A (es) |
| KR (1) | KR20090085599A (es) |
| AR (1) | AR062795A1 (es) |
| AU (1) | AU2007304508A1 (es) |
| BR (1) | BRPI0719956A2 (es) |
| CA (1) | CA2664700A1 (es) |
| CO (1) | CO6180444A2 (es) |
| CR (1) | CR10703A (es) |
| IL (1) | IL197817A0 (es) |
| MA (1) | MA30824B1 (es) |
| MX (1) | MX2009003617A (es) |
| NO (1) | NO20091735L (es) |
| PA (1) | PA8747601A1 (es) |
| PE (1) | PE20081173A1 (es) |
| SV (1) | SV2009003205A (es) |
| TN (1) | TN2009000100A1 (es) |
| TW (1) | TW200820988A (es) |
| UY (1) | UY30596A1 (es) |
| WO (1) | WO2008040441A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011089267A1 (en) * | 2010-01-25 | 2011-07-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Silylated biomolecules |
| JP5717138B2 (ja) * | 2011-05-23 | 2015-05-13 | 独立行政法人産業技術総合研究所 | タンパク質固定化表面修飾材料 |
| CN105452262A (zh) * | 2013-06-06 | 2016-03-30 | 日产化学工业株式会社 | 烷氧基硅烷化合物、液晶取向剂、液晶取向膜和液晶表示元件 |
| JP7266365B2 (ja) * | 2015-05-26 | 2023-04-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 分子および生体分子の１８ｆ標識化に有用な新規な複素芳香環フッ化ケイ素アクセプタおよびその調製方法 |
| DE112018005145T5 (de) | 2017-09-15 | 2020-07-23 | The Regents Of The University Of California | Hemmung von aminoacylase 3 (aa3) bei der behandlung von krebs |
| WO2021226076A1 (en) * | 2020-05-04 | 2021-11-11 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for detection of bacterial infection |
| US20230357100A1 (en) * | 2020-09-28 | 2023-11-09 | National Institutes for Quantum Science and Technology | Method for producing radioactive labeled substance, device for producing radioactive labeled substance, and method for evaporatively concentrating radioactive metal nuclide |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5084555A (en) * | 1989-08-21 | 1992-01-28 | The Administrators Of The Tulane Educational Fund | An octapeptide bombesin analog |
| US5732578A (en) * | 1995-02-24 | 1998-03-31 | Hyundai Metal Co., Ltd. | Device for maintaining the horizontality of a door lock lever |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| US6639076B1 (en) * | 1998-08-18 | 2003-10-28 | Eli Lilly And Company | Growth hormone secretagogues |
| ATE303988T1 (de) * | 1999-06-14 | 2005-09-15 | Lilly Co Eli | Inhibitoren von serin proteasen |
| WO2002044144A2 (en) * | 2000-11-30 | 2002-06-06 | Advanced Research And Technology Institute, Inc. | Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds |
| GB0206750D0 (en) * | 2002-03-22 | 2002-05-01 | Amersham Plc | Radiofluorination methods |
| EP1597270A2 (en) * | 2003-02-20 | 2005-11-23 | University of South Florida | Peptidomimetic inhibitors of stat3 activity and their medical uses |
| GB0305704D0 (en) * | 2003-03-13 | 2003-04-16 | Amersham Plc | Radiofluorination methods |
| WO2005077967A1 (en) * | 2004-02-13 | 2005-08-25 | The University Of British Columbia | Radiolabeled compounds and compositions, their precursors and methods for their production |
| US20080029548A1 (en) * | 2006-05-05 | 2008-02-07 | Ann De Wree | Fabric treatment dispensing package |
-
2007
- 2007-09-07 WO PCT/EP2007/008044 patent/WO2008040441A2/en not_active Ceased
- 2007-09-07 KR KR1020097009044A patent/KR20090085599A/ko not_active Withdrawn
- 2007-09-07 AU AU2007304508A patent/AU2007304508A1/en not_active Abandoned
- 2007-09-07 MX MX2009003617A patent/MX2009003617A/es not_active Application Discontinuation
- 2007-09-07 CA CA002664700A patent/CA2664700A1/en not_active Abandoned
- 2007-09-07 US US11/851,936 patent/US20090035215A1/en not_active Abandoned
- 2007-09-07 EP EP07818173A patent/EP2074135A2/en not_active Withdrawn
- 2007-09-07 JP JP2009530773A patent/JP2010505776A/ja active Pending
- 2007-09-07 BR BRPI0719956-2A2A patent/BRPI0719956A2/pt not_active IP Right Cessation
- 2007-09-10 TW TW096133834A patent/TW200820988A/zh unknown
- 2007-09-14 PE PE2007001246A patent/PE20081173A1/es not_active Application Discontinuation
- 2007-09-14 UY UY30596A patent/UY30596A1/es not_active Application Discontinuation
- 2007-09-14 PA PA20078747601A patent/PA8747601A1/es unknown
- 2007-09-14 AR ARP070104086A patent/AR062795A1/es unknown
-
2009
- 2009-03-25 TN TN2009000100A patent/TN2009000100A1/fr unknown
- 2009-03-26 IL IL197817A patent/IL197817A0/en unknown
- 2009-04-01 CR CR10703A patent/CR10703A/es not_active Application Discontinuation
- 2009-04-02 SV SV2009003205A patent/SV2009003205A/es not_active Application Discontinuation
- 2009-04-02 CO CO09034043A patent/CO6180444A2/es not_active Application Discontinuation
- 2009-04-30 MA MA31834A patent/MA30824B1/fr unknown
- 2009-04-30 NO NO20091735A patent/NO20091735L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008040441A2 (en) | 2008-04-10 |
| CR10703A (es) | 2009-06-25 |
| US20090035215A1 (en) | 2009-02-05 |
| IL197817A0 (en) | 2009-12-24 |
| JP2010505776A (ja) | 2010-02-25 |
| KR20090085599A (ko) | 2009-08-07 |
| SV2009003205A (es) | 2009-10-19 |
| TW200820988A (en) | 2008-05-16 |
| WO2008040441A3 (en) | 2009-01-08 |
| AU2007304508A8 (en) | 2009-05-14 |
| PE20081173A1 (es) | 2008-11-06 |
| NO20091735L (no) | 2009-06-30 |
| PA8747601A1 (es) | 2009-08-26 |
| TN2009000100A1 (en) | 2010-08-19 |
| UY30596A1 (es) | 2008-05-02 |
| MA30824B1 (fr) | 2009-10-01 |
| BRPI0719956A2 (pt) | 2014-04-29 |
| CO6180444A2 (es) | 2010-07-19 |
| MX2009003617A (es) | 2009-04-22 |
| CA2664700A1 (en) | 2008-04-10 |
| AU2007304508A1 (en) | 2008-04-10 |
| EP2074135A2 (en) | 2009-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062795A1 (es) | Marcacion con fluor radioactivo para diagnostico por imagenes | |
| ES2540204T3 (es) | Formulaciones farmacéuticas de inhibidores de la HDAC | |
| ES2543007T3 (es) | Micropartículas que comprenden sales de dicetopiperazina para la administración de fármacos | |
| BR0211317A (pt) | Sistema para a liberação controlada de uma droga por meio de retenção gástrica | |
| JP2008522981A5 (es) | ||
| ES2156699B1 (es) | "preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion". | |
| GT200100174A (es) | Proceso para la fabricacion de acidos n-aril-antranilicos y sus derivados. | |
| CO6260141A2 (es) | Inhibidores del co-transportador 2 sodio glucosa y metodos para la preparacion de los mismos y sus intermediarios | |
| AR045906A1 (es) | Composicion farmaceutica para mejorar la solubilidad de farmacos hidrofobicos | |
| PE20171095A1 (es) | Acidos grasos novedosos y su uso en la conjugacion con biomoleculas | |
| AR035365A1 (es) | Compuesto peptidico que comprende un centro inhibidor de la metionina aminopeptidasa 2 (metap-2) y su uso para preparar un medicamento | |
| AR077701A1 (es) | Compuestos antiproliferativos, conjugados de los mismos, procedimientos para estos, y usos de los mismos | |
| UY31867A (es) | Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992 | |
| BR0008759A (pt) | Métodos para a produção de proteinas contendo resìduos de cisteina livre | |
| CY1111934T1 (el) | Σταθεροποιημενες φαρμακευτικες συνθεσεις οι οποιες περιεχουν φεσοτεροδινη | |
| CO5221123A1 (es) | Desodorante con pequenas particulas de oxido de zinc | |
| AR059767A1 (es) | Profarmacos de analogos de cc-1065 y sus conjugados, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende y el uso de estos para la fabricacion de un medicamento para el tratamiento del cancer. | |
| HRP20210183T1 (hr) | 18f-obilježeni inhibitori specifičnog membranskog antigena prostate (psma) i njihova uporaba kao sredstava za vizualizaciju raka prostate | |
| JP2015532641A5 (es) | ||
| KR101968732B1 (ko) | 세포소기관에서 자가조립 가능한 펩타이드 분자를 포함하는 접합체 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 | |
| JP2019524798A5 (es) | ||
| AR110441A1 (es) | Derivados de ácidos hidroxámicos utilizables en el tratamiento de infección con mannheimia haemolytica o histophilus somni | |
| ES2770113T3 (es) | Análogos de la cisteamina resistentes a la ADO y sus usos | |
| BR112022012986A2 (pt) | Soluções orais compreendendo sais de lisdexamfetamina | |
| RU2006144279A (ru) | Пептидные соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |